For the Inventor, By the Inventor

Enter assignee name

Cambridge, United Kingdom

Mission Therapeutics Limited

USPTO Granted Patents = 31

EPO Patents = 21

Forward Citations = 30

Loading Chart...

Loading Chart...

17 inventors (with patents filed for the assignee):

Mark Kemp (28 out of 29 patents)

Martin Stockley (27 out of 31 patents)

Alison Jones (19 out of 25 patents)

4. Andrew Madin (14 out of 52 patents)

5. Karl Richard Gibson (11 out of 24 patents)

6. Gavin Alistair Whitlock (11 out of 29 patents)

7. Michael David Woodrow (10 out of 10 patents)

8. Xavier Jacq (2 out of 2 patents)

9. Stephen Philip Jackson (1 out of 18 patents)

10. Helen Robinson (1 out of 1 patent)

11. Yaara Ofir-Rosenfeld (1 out of 1 patent)

12. Paul Wijnhoven (1 out of 1 patent)

13. Ryotaro Nishi (1 out of 1 patent)

14. Keith Allan Menear (1 out of 1 patent)

15. Quentin Gueranger (1 out of 1 patent)

31 patents: Sort by Forward Citations

1. 11993595 - Compounds (2024-05-28),

2. 11958833 - Compounds (2024-04-16),

3. 11945797 - 1-cyano-pyrrolidine derivatives as dub inhibitors (2024-04-02),

4. 11472798 - Compounds (2022-10-18),

5. 11414402 - Sulfonamide-substituted cyanopyrrolidines with activity as DUB inhibitors (2022-08-16),

6. 11390584 - 1-cyano-pyrrolidine compounds as USP30 inhibitors (2022-07-19),

7. 11370784 - Cyano-substituted heterocycles with activity as inhibitors of USP30 (2022-06-28),

8. 11352339 - 1-cyano-pyrrolidine derivatives as DUB inhibitors (2022-06-07),

9. 11319287 - Cyanopyrrolidines as dub inhibitors for the treatment of cancer (2022-05-03),

10. 11306096 - 4,6 dihydropyrrolo [3,4-C] pyrazole-5 (1H)-carbonitrile derivates for treating cancer (2022-04-19),

11. 11236092 - Spiro-condensed pyrrolidine derivatives as deubiquitylating enzymes (DUB) inhibitors (2022-02-01),

12. 11130748 - Compounds (2021-09-28),

13. 11091488 - 1-cyano-pyrrolidine derivatives as inhibitors of USP30 (2021-08-17),

14. 11084821 - Cyanopyrrolidine derivatives with activity as inhibitors of USP30 (2021-08-10),

15. 11066365 - 1-cyano-pyrrolidine compounds as USP30 inhibitors (2021-07-20),

Mission Therapeutics is a drug discovery and development company focused on selectively targeting deubiquitylating enzymes (DUBs) to discover innovative treatments for diseases with high unmet medical need. The company utilizes its proprietary DUB targeting platform to develop small molecule drugs that modulate DUB activity, aiming to restore cell function in various diseases including neurodegenerative disorders, fibrosis, and cancer. Through strategic collaborations and internal programs, Mission Therapeutics aims to deliver transformative therapies to patients.

This text is generated by artificial intelligence and may not be accurate.

Company Badge

USPTO Data Jan 1 1976 - Dec 30 2025

31 Patents

#30 in Cambridge

#567 in United Kingdom

#20,639 in the World

Cambridge, United Kingdom

Mission Therapeutics Limited

Forward Citations = 30

17 inventors:

Mark Kemp (28 out of 29 patents)

Martin Stockley (27 out of 31 patents)

Alison Jones (19 out of 25 patents)

4. Andrew Madin (14 out of 52 patents)

5. Karl Richard Gibson (11 out of 24 patents)

Please report any incorrect information to support@idiyas.com

Loading…